โš ๏ธ Medical Notice: If you are experiencing a medical emergency, call 911 or go to the nearest ER. This directory is an educational resource and not an emergency medical service.
๐Ÿ›๏ธ Verified NIH Protocol โ€ข Sourced via U.S. National Library of Medicine (Last Synced: 2026-06-23)

Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms

๐ŸŸข Recruiting Protocol / Phase N/A โš™๏ธ Medical Device Protocol Sponsor: Gerd Care Medical Ltd

๐Ÿฉบ Protocol Summary

The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD). The main questions this research aims to answer are: 1. Does the eGERD device reduce acidity in the esophagus? 2. Does the eGERD device reduce GERD symptoms such as heartburn and regurgitation? 3. What medical problems do participants have when using the eGERD device? To assess the acidity in the esophagus, a wireless standard-of-care capsule called Bravo will be placed in the participants esophagus (throat) for several days. To assess GERD symptoms, participants will be requested to report symptoms they experience using a smartphone application. Researchers will compare a real version of the eGERD device to a sham version (a look-alike device that has no therapeutic effect) to see if the eGERD device is effective in treating GERD.

Primary Research Facility: Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University (Chicago, Illinois)

๐Ÿ“‹ Basic Study Criteria & Logistics Checklist

0 of 3 Checked

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

๐Ÿ“ Primary Site Map

Site: Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University โ€” Chicago, Illinois

๐Ÿ“ All Participating Trial Locations (5 Sites)

Multi-Center Trial

This protocol is enrolling participants across multiple clinical centers:

1. Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University โ€” Chicago, Illinois โ€ข Contact: (312) 695-0182
2. Gastroenterology department, Emek medical center (EMC) โ€” United States โ€ข Contact: 972544508118
3. Gastroenterology department, Rambam Health Care Campus โ€” United States โ€ข Contact: 972502061142
4. Gastroenterology department, Rabin medical center (RMC) โ€” United States โ€ข Contact: 972523428692
5. Gastroenterology department, Tel Aviv Sourasky Medical Center (Ichilov) โ€” United States โ€ข Contact: 97236974281

๐Ÿ“„ Print Doctor Discussion Sheet

Preview and print a 1-page summary with 5 tailored questions for your physician.

๐Ÿ’ฐ Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act ยง 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

๐Ÿ’ก Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.

๐Ÿ›๏ธ Official Government Provenance

NIH ClinicalTrials.gov Protocol Record

NCT Identifier: NCT06613438 โ€ข Last Synced: 2026-06-23
View on ClinicalTrials.gov โ†—
๐Ÿ“ž Call Desk ๐Ÿ“‹ Check Criteria